Literature DB >> 25458500

Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs.

Jong Hyun Cho1, Lavanya Bondana1, Mervi A Detorio1, Cathy Montero1, Leda C Bassit1, Franck Amblard1, Steven J Coats2, Raymond F Schinazi1.   

Abstract

The synthesis of 9-(β-d-1,3-dioxolan-4-yl)2,6-diaminopurine nucleoside phosphoramidate prodrugs as well as various 2-amino-6-carbamoylpurine dioxolane derivatives and their phosphoramidates prodrugs is reported. Their ability to block HIV and HBV replication along with their cytotoxicity toward HepG2, human lymphocyte, CEM and Vero cells was also assessed. Published by Elsevier Ltd.

Entities:  

Keywords:  Anti-HBV; Anti-HIV; Antiviral agent; DAPD; β-d-1,3-Dioxolan-4-yl nucleosides

Mesh：

Substances：

Year:  2014        PMID： 25458500      PMCID： PMC4312240          DOI： 10.1016/j.bmc.2014.10.003

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN： 0968-0896            Impact factor:   3.641


  32 in total

1.  Current insights into reverse transcriptase inhibitor-associated resistance.

Authors:  M A Wainberg; A J White
Journal:  Antivir Ther       Date:  2001

2.  Comparative Quantitative Structureminus signActivity Relationship Studies on Anti-HIV Drugs.

Authors:  Rajni Garg; Satya P. Gupta; Hua Gao; Mekapati Suresh Babu; Asim Kumar Debnath; Corwin Hansch
Journal:  Chem Rev       Date:  1999-12-08       Impact factor: 60.622

3.  Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses.

Authors:  Lavanya Bondada; Mervi Detorio; Leda Bassit; Sijia Tao; Catherine M Montero; Tyana M Singletary; Hongwang Zhang; Longhu Zhou; Jong-Hyun Cho; Steven J Coats; Raymond F Schinazi
Journal:  ACS Med Chem Lett       Date:  2013-08-08       Impact factor: 4.345

Review 4.  Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?

Authors:  Youcef Mehellou; Erik De Clercq
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

5.  Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase.

Authors:  N Yahi; C Tamalet; C Tourrès; N Tivoli; J Fantini
Journal:  J Biomed Sci       Date:  2000 Nov-Dec       Impact factor: 8.410

Review 6.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

7.  Resistance issues with new nucleoside/nucleotide backbone options.

Authors:  Mark A Wainberg; Dan Turner
Journal:  J Acquir Immune Defic Syndr       Date:  2004-09-01       Impact factor: 3.731

8.  Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes.

Authors:  Catherine Tamalet; Jacques Fantini; Christian Tourres; Nouara Yahi
Journal:  AIDS       Date:  2003-11-07       Impact factor: 4.177

Review 9.  Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.

Authors:  Joel E Gallant; Peter Z Gerondelis; Mark A Wainberg; Nancy S Shulman; Richard H Haubrich; Marty St Clair; Ernest R Lanier; Nicholas S Hellmann; Douglas D Richman
Journal:  Antivir Ther       Date:  2003-12

Review 10.  Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.

Authors:  Lisa F Rezende; Vinayaka R Prasad
Journal:  Int J Biochem Cell Biol       Date:  2004-09       Impact factor: 5.085
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.